Related references
Note: Only part of the references are listed.The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T. Flaherty et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K. S. Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd et al.
NATURE MEDICINE (2020)
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Mary W. Redman et al.
LANCET ONCOLOGY (2020)
NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations
Philippe L. Bedard et al.
CANCER RESEARCH (2019)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Share Paper
